Proactive Investors - Run By Investors For Investors

Genprex boosts outreach to investors with planned launch of corporate website

The new site will include presentations, stock charts, SEC filings, news and media coverage
Oncoprex symbol
Genprex will also be forging partnerships with PR firms to improve publicity efforts

Gene-therapy company Genprex Inc (NASDAQ:GNPX) is boosting its outreach efforts to investors with the launch of a corporate website in 2019 and new email alerts.

The new site will include presentations, stock charts, SEC filings, news, media coverage and tailored email newsletters.

As part of this roll-out, investors already can receive news regarding Genprex in their inboxes by signing up for the company’s communication list here.

On top of its investor relations push, Genprex will also be forging partnerships with media relations and public relations firms to get its message out.

READ: Genprex licenses additional cancer-fighting technologies from University of Texas

“We’re extremely excited about the added emphasis on investor communications and relations in the new year,” said Genprex CEO Rodney Varner in a statement. “With the new website and email newsletters we will be launching, we intend to provide to current and potential investors unprecedented insight into what is happening at Genprex as we continue to work at the forefront of the new age of immunogene therapy cancer treatments.”

Based in Austin, Texas, Genprex is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

In August, Genprex entered into a collaboration with The University of Texas MD Anderson Cancer Center to extend two option agreements between Genprex and MD Anderson pertaining to the use of TUSC2, the active agent in Oncoprex.

The company has also recently hired Jan Stephens, RN, in its Cambridge office as Genprex’s new vice-president of clinical operations. Stephens, who has more than 20 years of clinical experience in the biopharma industry, is being tasked with supporting the various clinical development programs for Oncoprex.

Genprex shares rose 7.7% to $1.26 in Wednesday’s morning trading session.

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

A syringe
January 30 2019
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use